MedTrace Logo

Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer

NCT02556762 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2024-02-06

No results posted yet for this study

Summary

This randomized phase III trial is to compare simultaneous modulated accelerated boost with standard dose radiotherapy given together with chemotherapy in treating patients with esophageal squamous cell carcinoma.

Conditions

  • Esophageal Cancer

Interventions

RADIATION

Radiotherapy with simultaneous modulated accelerated boost

Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases

RADIATION

Standard dose radiotherapy

Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease

DRUG

PF

Chemotherapy: Cisplatin and 5fluorouracil

Sponsors & Collaborators

  • Chuangzhen Chen

    lead OTHER

Principal Investigators

  • Chuangzhen Chen, MD · Cancer Hospital, Shantou University Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2022-03-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556762 on ClinicalTrials.gov